Paper32192585
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Lan Z and 22 others. Lancet Respir Med, 2020. Cited by 203 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Papers, record 32192585. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32192585
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
- PubMed
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Systematic Review, Network Meta-Analysis
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antitubercular Agents | Major topic |
| Drug-Related Side Effects and Adverse Reactions | Major topic |
| Tuberculosis, Multidrug-Resistant | Major topic |
| Tuberculosis, Pulmonary | Major topic |
| Adult | |
| Aminosalicylic Acid | |
| Canada | |
| Clofazimine | |
| Diarylquinolines | |
| Female | |
| Fluoroquinolones | |
| Humans | |
| Incidence | |
| Linezolid | |
| Male | |
| Mycobacterium tuberculosis |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| 001 | World Health Organization | International | PubMed | PubMed | |
| D43 TW007124 | FIC NIH HHS | United States | D43TW007124 | PubMed and NIH | NIH RePORTER |
References64
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29,122,917 | Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens. | Eur Respir J | 2017 | https://conductscience.org/library/papers/29122917 | PubMed |
| 2 | 28,656,130 | Tuberculosis control, and the where and why of artificial intelligence. | ERJ Open Res | 2017 | https://conductscience.org/library/papers/28656130 | PubMed |
| 3 | 29,037,291 | The devil we know: is the use of injectable agents for the treatment of MDR-TB justified? | Int J Tuberc Lung Dis | 2017 | https://conductscience.org/library/papers/29037291 | PubMed |
| 4 | 17,988,949 | Meta-analysis for ranked discovery datasets: theoretical framework and empirical demonstration for microarrays. | Comput Biol Chem | 2008 | https://conductscience.org/library/papers/17988949 | PubMed |
| 5 | 19,494,215 | The diarylquinoline TMC207 for multidrug-resistant tuberculosis. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19494215 | PubMed |
| 6 | 26,965,290 | Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. | Eur Respir J | 2016 | https://conductscience.org/library/papers/26965290 | PubMed |
| 7 | 20,185,428 | Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004. | Eur Respir J | 2010 | https://conductscience.org/library/papers/20185428 | PubMed |
| 8 | 23,735,593 | Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis. | Int J Tuberc Lung Dis | 2013 | https://conductscience.org/library/papers/23735593 | PubMed |
| 9 | 20,356,997 | Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective. | Eur Respir J | 2010 | https://conductscience.org/library/papers/20356997 | PubMed |
| 10 | 18,083,461 | The binomial distribution of meta-analysis was preferred to model within-study variability. | J Clin Epidemiol | 2008 | https://conductscience.org/library/papers/18083461 | PubMed |
| 11 | 26,985,890 | Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review. | Int J Mol Sci | 2016 | https://conductscience.org/library/papers/26985890 | PubMed |
| 12 | 28,419,314 | Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis. | J Antimicrob Chemother | 2017 | https://conductscience.org/library/papers/28419314 | PubMed |
| 13 | 23,018,916 | Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. | Eur Respir J | 2013 | https://conductscience.org/library/papers/23018916 | PubMed |
| 14 | 20,132,617 | Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. | Int J Tuberc Lung Dis | 2010 | https://conductscience.org/library/papers/20132617 | PubMed |
| 15 | 24,384,902 | Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. | BMJ Open | 2014 | https://conductscience.org/library/papers/24384902 | PubMed |
| 16 | 18,976,552 | Multidrug- and extensively drug-resistant tuberculosis, Germany. | Emerg Infect Dis | 2008 | https://conductscience.org/library/papers/18976552 | PubMed |
| 17 | 15,971,391 | Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. | Int J Tuberc Lung Dis | 2005 | https://conductscience.org/library/papers/15971391 | PubMed |
| 18 | 27,334,498 | Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis. | Ann Clin Microbiol Antimicrob | 2016 | https://conductscience.org/library/papers/27334498 | PubMed |
| 19 | 28,529,205 | Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. | Eur Respir J | 2017 | https://conductscience.org/library/papers/28529205 | PubMed |
| 20 | 28,331,044 | Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil. | Eur Respir J | 2017 | https://conductscience.org/library/papers/28331044 | PubMed |
Cited by143
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 203 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,890,781 | Treatment outcomes and post-treatment mortality among people with multidrug/rifampicin-resistant tuberculosis in Sierra Leone: a national cohort study. | Lancet Reg Health Afr | 2026 | https://conductscience.org/library/papers/42890781 | PubMed |
| 42,757,111 | Challenges in causality assessment of renal dysfunction during sequential treatment for presumed rifampicin-resistant tuberculosis in an elderly patient. | IDCases | 2026 | https://conductscience.org/library/papers/42757111 | PubMed |
| 42,746,380 | Real-world treatment outcomes and adverse events during BPaLM therapy for rifampicin-resistant TB. | IJTLD Open | 2026 | https://conductscience.org/library/papers/42746380 | PubMed |
| 42,638,850 | Evaluation of a short, all oral treatment regimen including bedaquiline, delamanid, linezolid, clofazimine, and pyrazinamide named "Regimen C" for pre-XDR tuberculosis in Niger. | Front Tuberc | 2025 | https://conductscience.org/library/papers/42638850 | PubMed |
| 42,517,152 | Characteristics, Treatment Strategies, and Long-term Health Outcomes of People With Bedaquiline-resistant Tuberculosis in Karakalpakstan, Uzbekistan-A Retrospective Cohort Study. | Open Forum Infect Dis | 2026 | https://conductscience.org/library/papers/42517152 | PubMed |
| 42,121,320 | Adverse events in bedaquiline- and pretomanid-based regimens for drug-resistant tuberculosis from trial, implementation and pharmacovigilance studies. | Br J Clin Pharmacol | 2026 | https://conductscience.org/library/papers/42121320 | PubMed |
| 42,094,621 | Molecular Mechanisms of Resistance and Treatment Efficacy of Delamanid Against Mycobacterium tuberculosis: A Systematic Review. | Health Sci Rep | 2026 | https://conductscience.org/library/papers/42094621 | PubMed |
| 42,036,916 | Factors Associated With Tuberculosis Treatment Failure Among Hill Tribe and Stateless People in Chiang Rai Province, Thailand: A Case-Control Study. | Trop Med Int Health | 2026 | https://conductscience.org/library/papers/42036916 | PubMed |
| 42,012,189 | The Mycobacterium tuberculosis Rv0132c Gene Product Mtb-FGD2 Can Act as an F420-Dependent Glucose Dehydrogenase. | Proteins | 2026 | https://conductscience.org/library/papers/42012189 | PubMed |
| 42,010,496 | Towards precision dosing of contezolid: moderate hepatic impairment increases plasma concentration of contezolid in anti-tuberculosis treatment. | BMC Infect Dis | 2026 | https://conductscience.org/library/papers/42010496 | PubMed |
| 41,994,187 | Safety of treatment regimens for drug-resistant TB over a 15-year period: a scoping review. | IJTLD Open | 2026 | https://conductscience.org/library/papers/41994187 | PubMed |
| 41,957,325 | Contezolid in tuberculosis therapy: a retrospective analysis of real-world practice in China. | Eur J Clin Microbiol Infect Dis | 2026 | https://conductscience.org/library/papers/41957325 | PubMed |
| 41,888,729 | Cohort evaluation of an all-oral shorter regimen for drug-resistant tuberculosis in Ecuador. | BMC Infect Dis | 2026 | https://conductscience.org/library/papers/41888729 | PubMed |
| 41,877,621 | Adverse drug reactions among children with tuberculosis in China: a multicentre study, 2017-2022. | Ann Med | 2026 | https://conductscience.org/library/papers/41877621 | PubMed |
| 41,735,928 | Durable three-year outcomes and persistent neuropathy following nine-month all-oral regimens for rifampicin-resistant tuberculosis: a multicentre cohort study in China. | BMC Infect Dis | 2026 | https://conductscience.org/library/papers/41735928 | PubMed |
| 41,709,251 | Pattern and predictors of drug resistance and treatment outcome in tuberculosis patients at the centers of programmatic management of drug-resistant tuberculosis in Lahore, Pakistan. | BMC Public Health | 2026 | https://conductscience.org/library/papers/41709251 | PubMed |
| 41,559,620 | Success rates of DR-TB patients and associated factors in Tanzania: a six-year cohort study. | BMC Infect Dis | 2026 | https://conductscience.org/library/papers/41559620 | PubMed |
| 41,519,798 | Preparation and in vitro sustained release performance of thermosensitive gel microsphere composite loaded with Anti-Tuberculosis drug PaMZ/BMP-2. | J Orthop Surg Res | 2026 | https://conductscience.org/library/papers/41519798 | PubMed |
| 41,329,266 | The Structure, Properties, and Clinical Utility of Contezolid for Antituberculosis: A Narrative Review. | Infect Dis Ther | 2026 | https://conductscience.org/library/papers/41329266 | PubMed |
| 41,322,740 | Assessment of Medication Adherence to Anti-tuberculosis Treatment Among Patients With Tuberculosis at a Tertiary Care Hospital in South Gujarat, India. | Cureus | 2025 | https://conductscience.org/library/papers/41322740 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32192585
GET https://conductscience.org/api/papers/v1/32192585/authors?page=2